The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome

Depression, Anxiety Clinical Trial

— IBS  

Official title:

An Open Label Study to Assess the Impact of 'COMBO' on Mood, Stress and Bowel Symptoms in Adults With Irritable Bowel Syndrome (IBS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04422327
• Other study ID #: AFCRO-079
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: September 20, 2017
• Est. completion date: February 12, 2018

Study information

• Verified date: June 2020
• Source: PrecisionBiotics Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aimed to assess the impact of consumption of COMBO, a combination product of two Bifidobacterium longum strains, on stress, mood and bowel symptoms in adults with Irritable Bowel Syndrome (IBS).

Description:

This is an open label study designed to assess the impact on stress, mood and bowel symptoms & safety of COMBO, a combination of Bifidobacterium longum 35624® and Bifidobacterium longum 1714™ strains, when consumed once daily for 8 weeks, in adults with Irritable Bowel Syndrome (IBS). Volunteers will be screened according to the selection criteria in order to identify up to 40 female subjects, with recurrent abdominal pain/discomfort and mild to moderate stress/mood status. The study will involve 6 visits over an 18 to 20-week period [Screening period (Visit 1: week-2), Intervention period (Visit 2: week 0, Visit 3: week 4, Visit 4: week 8), and Follow-up/ Washout period (Visit 5: week 12, Visit 6: week 16)]. Participants will fill in daily and weekly eDiary from 1st visit onwards. Questionnaires will be administered from visit 2 to visit 6. Research blood and saliva will also be collected at these time points. Stool sample will be collected at Visit 2, 4, 5, 6.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: February 12, 2018
• Est. primary completion date: February 12, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

To be considered eligible for enrolment into the study, subjects must;

1. Be able to give written informed consent,

2. Be a Caucasian female, between 18 and 55 years of age,

3. Subject has Irritable Bowel Syndrome according to the Rome III Diagnostic Criteria:

Recurrent abdominal pain or discomfort** at least 3 days/month in the last 3 months associated with two or more of the following:

i. Improvement with defecation

ii. Onset associated with a change in frequency of stool

iii. Onset associated with a change in form (appearance) of stool

Criterion fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis

** "Discomfort" means an uncomfortable sensation not described as pain.

4. Subjects agree to complete symptom diaries and return completed diaries at all sessions,

5. Subjects with mild to moderate score (8-14) on the HADS-A and/or HADS-D questionnaire, Subjects will be excluded if there is greater than 1 point difference from the screening to baseline scores,

6. Be willing to refrain from taking any dietary supplements or other fermented foods that contain live bacteria during the study,

7. Be willing to refrain from taking any medications or preparations used in the therapy of IBS (herbal, dietary supplements, homeopathic preparations, etc.) during the study and from 4-weeks before the baseline visit,

8. Be willing to refrain from probiotic use 4 weeks before the baseline visit,

9. If using fiber supplements (e.g., Trifyba, Fybogel, Konsyl, Isogel, Regulan, Ispagel, Celevac, Normacol), the dose and regimen have remained stable for at least 30 days and the subject will continue the same dose and regimen throughout the length of the trial,

10. If using products that contain nicotine or caffeine, agrees to continue current usage levels throughout the length of the trial.

Exclusion Criteria:

Subjects will be excluded from the study if they meet any of the below criteria;

1. Are less than 18 and greater than 55 years of age at the time of consent,

2. Females are pregnant, lactating or wish to become pregnant during the study. Female subject is currently either of:

• non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or any female who is surgically sterilized (via documented hysterectomy or bilateral tubal ligation). (For purposes of this study, postmenopausal is defined as one year without menses), OR

• child bearing potential, the subject is eligible to enter and participate in this study if she is not lactating and has a negative urine pregnancy test at the screening visit, visit 2 and upon completion of the study at visit 7. The subject must also agree to one of the following methods of contraception:

i. Complete abstinence from intercourse two weeks prior to administration of study drug, throughout the clinical trial, until the completion of follow-up procedures or for two weeks following discontinuation of the study medication in cases where subject discontinues the study prematurely. (Subjects utilizing this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding 2 weeks when they present to the clinic for the Final Visit.) or,

ii. has a male sexual partner who is surgically sterilized prior to the Screen Visit and is the only male sexual partner for that subject or,

iii. sexual partner(s) is/are exclusively female or,

iv. Oral contraceptives (either combined or progestogen only) with double-barrier method of contraception consisting of spermicide with either condom or diaphragm. (Women of child-bearing potential using an oral contraceptive in combination with a double-barrier method of contraception are required to continue to use this form of contraception for 1 week following discontinuation of study medication).

v. Use of double-barrier contraception, specifically, a spermicide plus a mechanical barrier (e.g. male condom, female diaphragm). The subject must be using this method for at least 1 week following the end of the study or,

vi. Use of any intrauterine device (IUD) or contraceptive implant with published data showing that the highest expected failure rate is less than 1% per year. The subject must have the device inserted at least 2 weeks prior to the first Screen Visit, throughout the study, and 2 weeks following the end of the study,

3. Are hypersensitive to any of the components of the test product,

4. Consumption of Alflorex probiotic for 6 months,

5. Consumption of any type of yoghurts or probiotic-containing products in the 4 weeks prior to the baseline visit,

6. Subjects who have been on antibiotics during the past month,

7. Concurrent systemic disease and/or laboratory abnormalities considered by Investigators to be risky or that could interfere with data collection,

8. Subjects who have a significant acute or chronic coexisting illness [cardiovascular, history of co-existing gastrointestinal, and/or gynecological, and/or urologic pathology (eg., colon cancer, colitis, Crohn's, celiac, endometriosis, prostate cancer) or lactose intolerance,

9. Subjects with inflammatory disorders (e.g. chronic fatigue syndrome (CDC criteria), psoriasis, rheumatoid arthritis or any other inflammatory arthropathies),

10. Subjects who are severely immunocompromised (HIV positive, transplant patient, on antirejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy within the last year),

11. Psychiatric diagnosis other than anxiety or depression,

12. Subjects who are on anti-depressants, anxiolytics, antipsychotics, anticonvulsants, centrally acting corticosteroids and/or opioid pain relievers in the last 6 months,

13. Subject has IBS symptoms that are predominantly related to menstruation,

14. Subject has a history of prior gastrointestinal surgery (apart from appendectomy),

15. Subjects who have had a previous cholecystectomy,

16. Subjects with a history of active cancer in the last 5 years (other than localized basal cell, squamous cell skin cancer or cancer in situ that has been resected),

17. Subjects with a history of drug and / or alcohol abuse at the time of enrolment,

18. Subject has a history of non-compliance,

19. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial,

20. If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study,

21. Have a malignant disease or any concomitant end-stage organ disease.

Related Conditions & MeSH terms

• Depression
• Depression, Anxiety
• IBS - Irritable Bowel Syndrome
• Irritable Bowel Syndrome
• Syndrome

Intervention

Dietary Supplement:
• Probiotic capsule
Each probiotic capsule contains 5 x 10^8 CFU B. longum 35624® and 5 x 10^8 CFU B. longum 1714™ with corn starch and magnesium stearate. The probiotic capsule will be supplied by PrecisionBiotics Ltd.

Locations

Country	Name	City	State
Ireland	Atlantia Food Clinical Trials Ltd.	Cork

Sponsors (2)

Lead Sponsor	Collaborator
PrecisionBiotics Ltd.	Atlantia Food Clinical Trials Ltd.

Country where clinical trial is conducted

Ireland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in stress and mood, assessed by Hospital Anxiety and Depression Scale (HADS) scores	HADS gives HADS-A and HADS-D scores; minimum score for each is 0, maximum score is 21. Higher scores indicate worse stress/mood.	Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.
Secondary	Change in Subject Global Assessment (SGA) of IBS symptoms, assessed by weekly eDiary	Participants answer the question: "Did you have adequate relief of your IBS symptoms over the past week?" Yes or No.	Assessed weekly from baseline to 8 weeks post supplement intake.
Secondary	Change in Subject Global Assessment (SGA) of abdominal pain/discomfort, assessed by weekly eDiary	Participants answer the question: "Did you have adequate relief of your abdominal pain and discomfort over the past week?" Yes or No.	Assessed weekly from baseline to 8 weeks post supplement intake.
Secondary	Change in IBS-Symptom Severity Score (IBS-SSS)	IBS-SSS is a composite score of abdominal pain, number of days with abdominal pain, bloating/distension, satisfaction with bowel habits, and IBS-related quality of life (QoL). Scores range from 0 to 500, with higher scores indicating worse symptoms.	Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.
Secondary	Change in stool frequency, assessed by daily eDiary	Daily diary of number of bowel movements.	Assessed daily from baseline to 8 weeks post supplement intake.
Secondary	Change in stool consistency (Bristol Stool Scale), assessed by daily eDiary	Daily diary of stool consistency of each bowel movement based on Bristol Stool Scale (Type 1-7).	Assessed daily from baseline to 8 weeks post supplement intake.
Secondary	Change in abdominal pain/discomfort, assessed by daily eDiary	Daily diary of Visual Analog Scale (VAS) of abdominal pain/discomfort.	Assessed daily from baseline to 8 weeks post supplement intake.
Secondary	Change in abdominal bloating/distension, assessed by daily eDiary	Daily diary of Visual Analog Scale (VAS) of abdominal bloating/distension.	Assessed daily from baseline to 8 weeks post supplement intake.
Secondary	Change in bowel movement urgency, assessed by daily eDiary	Daily diary of Visual Analog Scale (VAS) of bowel movement urgency.	Assessed daily from baseline to 8 weeks post supplement intake.
Secondary	Change in straining, assessed by daily eDiary	Daily diary of Visual Analog Scale (VAS) of straining.	Assessed daily from baseline to 8 weeks post supplement intake.
Secondary	Change in passage of gas, assessed by daily eDiary	Daily diary of Visual Analog Scale (VAS) of passage of gas.	Assessed daily from baseline to 8 weeks post supplement intake.
Secondary	Change in Visceral Sensitivity Index	Visceral Sensitivity Index (VSI) is a self-report measure of the gastrointestinal symptom-specific anxiety (GSA) of patients with IBS, in terms of cognitive, emotional and behavioral responses. Sum scores range from 0 to 75 with higher scores indicating more severe GI-specific anxiety.	Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.
Secondary	Change in sleep quality, assessed by Pittsburgh Sleep Quality Index (PSQI)	PSQI global score: minimum score is 0, maximum score is 21. Higher scores indicate worse sleep quality.	Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.
Secondary	Change in cognition, assessed by Visual Analogue Scales	This assessment measures individual question answers related to hedonic tone, anxiety and alertness.	Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.
Secondary	Change in cognition, assessed by spatial span test	This test measures span length, errors, number of attempts and latency.	Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.
Secondary	Change in cognition, assessed by Stockings of Cambridge test	This test measures problems solved in minimum moves, mean moves per n-move problem, initial thinking time per n-move problems and subsequent thinking time per n-move problems.	Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.
Secondary	Change in cognition, assessed by Paired Associates Learning test	This test measures errors, trials, memory scores and stages completed.	Assessed at baseline, 4 and 8 weeks of supplement intake, and 4 and 8 weeks post supplement intake.
Secondary	Safety of the investigational product, assessed by number of participants with treatment-related adverse events	Safety will be evaluated throughout the study on the basis of incidence of treatment-related serious and non-serious adverse events.	Assessed through study completion, an average of 6 months.